Vor Bio announced on July 17, 2025, the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately. Dr. Zuraw brings over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases.
Notably, she previously served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was a key leader in the successful development and execution of clinical trials for telitacicept. Her direct experience with telitacicept, which Vor Bio recently licensed, is highly strategic.
Dr. Zuraw played a central role in achieving regulatory approvals in China for telitacicept across multiple indications, including systemic lupus erythematosus, generalized myasthenia gravis, and rheumatoid arthritis. Her expertise will be invaluable as Vor Bio executes its late-stage development programs globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.